Scott Bingham, MD
Interventional Cardiology · Provo, UTNPI 1487612214
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 60 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Novartis at 50.0% of the total. Reporting peaked in 2023 at $266 and has fallen 88.8% since, to $30 in 2025. That places this record below the midpoint for interventional cardiology clinicians in UT, where the typical reported total is $5,946.
Across 60 payments — averaging $19.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$576
- Johnson & Johnson$96
- Pfizer$83
- Canon Medical Systems USA, Inc.$68
- Actelion Pharmaceuticals US, Inc.$52
- Hologic Sales And Service, LLC$50
- plus $228 from 8 others
What the payments were for
- Food & beverage$1,13899%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 30 | $576 |
| Johnson & Johnson | 6 | $96 |
| Pfizer | 6 | $83 |
| Canon Medical Systems USA, Inc. | 1 | $68 |
| Actelion Pharmaceuticals US, Inc. | 3 | $52 |
| Hologic Sales And Service, LLC | 2 | $50 |
| Heartflow, Inc. | 2 | $50 |
| Inspire Medical Systems, Inc. | 3 | $43 |
| Abbott | 2 | $39 |
| Lantheus Medical Imaging, Inc. | 1 | $29 |
| Novo Nordisk | 1 | $23 |
| Sanofi Pasteur Inc. | 1 | $15 |
| AstraZeneca | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
How this compares
$1,152 in reported general payments places this provider in the 15th percentile of 45 interventional cardiology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 471 | $526,390 |
| XareltoRivaroxaban | 145 | $204,967 |
| JardianceEmpagliflozin | 71 | $67,974 |
| EntrestoSacubitril/Valsartan | 80 | $61,640 |
| Atorvastatin Calcium | 1,975 | $26,437 |
| Metoprolol Succinate | 825 | $15,162 |
| Carvedilol | 934 | $12,340 |
| Rosuvastatin Calcium | 629 | $11,425 |
| Potassium Chloride | 466 | $10,098 |
| Repatha SureclickEvolocumab | 13 | $7,084 |
| Prasugrel Hcl | 75 | $6,698 |
| Lisinopril | 638 | $5,573 |
| Amlodipine Besylate | 627 | $5,550 |
| Losartan Potassium | 424 | $5,335 |
| ClopidogrelClopidogrel Bisulfate | 382 | $4,914 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $83 | $526,390471 claims |
| Johnson & JohnsonXarelto | $96 | $204,967145 claims |
| Boehringer IngelheimJardiance | $13 | $67,97471 claims |
| NovartisEntresto | $576 | $61,64080 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 45 interventional cardiology providers in Utah.
Other interventional cardiology in Provo
- Daniel BennettProvo$12K
- James FeeneyProvo$7K
- Jonathan HolbrookProvo$6K
- Vamsee YagantiSalt Lake City$390K
- Blake GardnerSt George$267K
- Anwar TandarSalt Lake City$131K
- Sanjeev TrehanOgden$95K
- Stavros DrakosSalt Lake City$79K
- Tareq HarbOgden$27K
- Frederick WeltSalt Lake City$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.